Approval history In December 2009 VIVUS, Inc. submitted a new drug application (NDA) to the FDA and on March 1, 2010, VIVUS, Inc. announced that the FDA accepted the NDA for review.

On 22 December 2009 a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States.

Finally, I came through Cairo, where I consulted with Minister Omar Suleiman, because the National Democratic Alliance (NDA) negotiations, including eastern Sudan, are under Egyptian mediation.

During the period of the five year programme, well established radiometric non destructive assay (NDA) measurements have been made on United Kingdom warheads and their fissile components.

Signed

Signed

Instruments signed

(Signed) S.

(Signed) K.

(Signed) T.

(Signed) I.

Certificate self signed

(Signed) Philippe Séguin

(Signed) Reşat Çağlar

(Signed) Adamantios Th.

(Signed) Riyad Mansour

(Signed) Andrey Denisov

(Signed) Javier Solana

(Signed) Philippe Séguin

(Signed) Philippe Séguin

(Signed) John Dauth

(Signed) Jianxi Wang

(Signed) Fuad Siniora

(Signed) Ileka Atoki

(Signed) Dziunik Aghajanian

(Signed) Marcello Spatafora

(Signed) Javier Solana

(Signed) Andrey Denisov

(Signed) Zdzisław Rapacki

(Signed) Adamantios Th.

(Signed) Lauro L.

(Signed) Joel Salek

(Signed) John Dauth

(Signed) Philippe Séguin

(Signed) Jan Eliasson

(Signed) Ugo Sessi

(Signed) Aymeric Chauprade

(Signed) Kairat ABUSSEITOV

(Signed) Kofi A.

(Signed) A. Denisov

(Signed) Alexander Yakovlev

(Signed) Jan Eliasson

(Signed) Ahmed A.

(Signed) Andrey Denisov

(Signed) Andrei Dapkiunas